focus -WSS

focus

author：focus 2025-08-25 05:55:04 Page View：9

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What causes an itch? Researchers may have solved the mystery
Next article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

comprehensive

At least 13 dead in Texas as scorching temps continue

1:17FirefighterEMTWilliamDorseyandfirefighterEMTRodrigoPinedatreatamigrantwomansufferingfromheatexha

Nobel honors Karikó and Weissman's enduring partnership

DrewWeissman(left)andKatalinKarikó,whoselongtimepartnershipwasrecognizedwithaNobelPrizeonMonday.Pegg

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

The Karikó problem: Lessons for funding basic research

AdobeNewscientificinstitutesarespringingupallovertheplacethesedays:ArcadiaScience,NewScience,ArcInst